Peptide transport through the blood-brain barrier. Final report 1 Jul 87-31 Dec 90

Technical Report · Tue Jan 15 04:00:00 EST 1991

OSTI ID:5324142

Partridge, W M

Most neuropeptides are incapable of entering the brain from blood owing to the presence of unique anatomical structures in the brain capillary wall, which makes up the blood-brain barrier (BBB). Such neuropeptides could be introduced into the bloodstream by intranasal insufflation and, thus, could have powerful medicinal properties (e.g., Beta-endorphin for the treatment of pain, vasopressin analogues for treatment of memory, ACTH analogues for treatment of post-traumatic epilepsy), should these peptides be capable of traversing the BBB. One such strategy for peptide delivery through the BBB is the development of chimeric peptides, which is the basis of the present contract. The production of chimeric peptides involves the covalent coupling of a nontransportable peptide (e.g., Beta-endorphin, vasopressin) to a transportable vector peptide (e.g., insulin, transferrin, cationized albumin, histone). The transportable peptide is capable of penetrating the BBB via receptor-mediated or absorptive-mediated transcytosis. Therefore, the introduction of chimeric peptides allows the nontransportable peptide to traverse the BBB via a physiologic piggy back mechanism.

• Research Organization: California Univ., Los Angeles, CA (United States)
• OSTI ID: 5324142
• Report Number(s): AD-A-233753/3/XAB; CNN: DAMD17-87-C-7137
• Country of Publication: United States
• Language: English

Related Subjects

550200* -- Biochemistry
59 BASIC BIOLOGICAL SCIENCES
ANATOMY
BIOLOGY
BLOOD VESSELS
BLOOD-BRAIN BARRIER
BODY
CAPILLARIES
CARDIOVASCULAR SYSTEM
DELIVERY
HORMONES
INSULIN
MEDICINE
MEMBRANE TRANSPORT
NERVES
NERVOUS SYSTEM
ORGANIC COMPOUNDS
ORGANS
PAIN
PEPTIDE HORMONES
PEPTIDES
PERMEABILITY
PITUITARY HORMONES
PROTEINS
SYMPTOMS
VASOPRESSIN
WALLS